Sonoma Pharmaceuticals, Inc. (SNOA) stock soared 38.79% in the current-market trading session at the price of $7.42 after the company launched its first over-the-counter products on Amazon in the U.S and Europe. SNOA is a leading global healthcare company. It develops and commercializes stabilized hypochlorous acid (HOCl) products for a broad range of health care treatments.
SNOA Launched First Over-the-Counter Products on Amazon
On 28th September 2021, SNOA published that it had launched MucoClyns on Amazon sites in Europe and Regenacyn Advanced Scar Gel and Ocucyn Eyelid & Eyelash Cleanser on Amazon.com. These over-the-counter consumer products are based on Microcyn technology and are now available for customer orders. CEO of SNOA, Amy Trombly, remarked that they are more than happy about making their reliable and efficient products available to consumers through the Amazon platform. They are working to deliver their clinically proven Microcyn Technology to a broad range of patients, he added.
Dental Care Line for Professional and Consumer Care
On 19th August 2021, SNOA reported the launch of two new dental products. Microdacyn Oral Care had launched in Switzerland for both professional and consumer use. OroGenix Oral Hygiene Rinse, produced in partnership with Gabriel Science, LLC., is the company’s second dental product in the United States. COO of the company, Bruce Thornton, remarked that they are excited to launch the oral rinse for dental offices in Europe and the U.S. Both Gabriel Science and Medical System are the company’s perfect partners to develop dental and oral care products. Their Microcyn technology is the next-generation formulation because of its antimicrobial effect, shelf stability, and security.
SNOA First Quarter 2022 Financial Results
On 16th August 2021, SNOA published an earnings report for its first fiscal quarter ended 30th June 2021. For the quarter ended 30th June 2021, total revenues were $3.7 million. It represents the drop of $2.1 million or 36% from $5.8 million for the same quarter of last year. Net loss was $1.1 million for the quarter ended 30th June 2021. It represents a gain of $391,000 or 55% compared to a net loss of $709,000 for the quarter ended 30th June 2020. The rise in net loss resulted from the higher sale of the Micromed business last year. For the first quarter of fiscal 2021, EBITDAS loss was $0.8 million. The EBITDAS loss was $0.6 million for the same quarter ended 30th June 2020.
